Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 943-434-4 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Read-across from analogue substances was applied.
Key value for risk assessment in analogy to RIVM decision for Alcamizer P93, dated 23 October 2007, BMS071023.03:
28-d NOAEL 1000 mg/kg bw/d (read-across from substance with EC no. 423-570-6)
For the analogue P93 RIVM concluded:
Based on the fact that the NOAEL of 1000 mg/kg bw/d from the 28-d study of the analogue is much higher than the NOAELs of the dissociation products, RIVM concluded that dissociation of the substance after oral exposure will either be at a very low rate, or will not occur at all, and is even more unlikely for dermal and inhalation exposure.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- Endpoint derived based on RIVM decision for Alcamizer P93, dated 23 October 2007, BMS071023.03).
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Based on the Dutch Competent Authority Risk Assessment dated October 23, 2007 (BMS071023.03) of Aluminium-magnesium-zinc-carbonate-
hydroxide (an analogue substance), Aluminium magnesium carbonate hydroxide is of no concern for man and need not be considered further - data currently available are sufficient to allow the notification of this substance above 1000 tonnes/year.
* Aluminium-magnesium-zinc-carbonate-hydroxide (EC no. 423-570-6):
Aluminium-magnesium-zinc-carbonate-hydroxide was tested in a subacute 28-day oral toxicity test (EEC-Directive 92/69 B.7 (according to GLP principles)):
The substance was administered (gavage) to female and male Wistar rats. The dose range was as follows: 0, 50, 200 and 1000 mg/kg bw/day for 28 days - 5 animals per group. No treatment related effect was observed. It was concluded that the NOAEL was 1000 mg/kg bw/day, the highest dose tested.
For chronic toxicity the NOAEL was derived from the NOAEL for Al3+ and the content of Al in the substance to be 481 mg/kg bw/d.
Supporting data [carbonato(2-)]hexadecahydroxybis(aluminium)hexamagnesium: 180 days oral gavage repeated dose toxicity test in rats:
NOAEL > 2000 mg/kg/day.
No data is available on dermal or inhalation toxicity.
For the analogue P93 RIVM concluded:
Based on the fact that the NOAEL of 1000 mg/kg bw/d from the 28-d study of the analogue is much higher than the NOAELs of the dissociation products, RIVM concluded that dissociation of the substance after oral exposure will either be at a very low rate, or will not occur at all, and is even more unlikely for dermal and inhalation exposure.
In view of the similar chemical nature and very low water solubility, the same reasoning is applicable to Aluminium magnesium carbonate hydroxide.
Justification for selection of repeated dose toxicity via oral route - systemic effects endpoint:
Reliable endpoint available for analogue.
Justification for classification or non-classification
Based on the current data for analogues and RIVM conclusion, no classification is needed for systemic toxicity after repeated exposure for
Aluminium magnesium carbonate hydroxide according to Regulation (EC) No 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.